{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 10 of 92', 'CR845-CLIN3103', 'periodically until the Open-label End-of-Treatment or Early', 'Termination Visit. ECGs will be monitored at the Open-label', 'End-of-Treatment or Early Termination Visit.', 'The number and reason(s) for missed dialysis as well as the use of', 'antipruritic medications will be recorded throughout the Open-label', 'Extension Phase.', 'The last dose of open-label study drug will be administered at the last', 'dialysis visit on Week 52, or Early Termination.', 'Follow-up Period', 'A final safety Follow-up Visit will be conducted 7-10 days after the', 'End-of-Treatment Visit of the Double-blind Treatment Period for', 'patients not participating in the Open-label Extension Phase, after the', 'End-of-Treatment Visit of the Open-label Extension Phase, or after the', 'Early Termination Visit during either the Double-blind Treatment', 'Period or the Open-label Extension Phase.', 'STUDY DRUG', 'Study drug will be supplied in glass vials containing an extractable', 'volume of at least 1.3 mL of CR845 at a concentration of 0.05 mg/mL', 'in 0.04M isotonic acetate buffer, pH 4.5.', 'REFERENCE', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be', 'PRODUCT', 'provided in glass vials containing an extractable volume of at least', '1.3 mL.', 'TREATMENT', 'Patients will be administered CR845 0.5 mcg/kg or placebo as a single', 'REGIMENS', 'IV bolus 3 times a week after each dialysis session for 12 weeks during', 'the Double-blind Treatment Period.', 'During the Open-label Treatment Period, patients will be administered', 'CR845 0.5 mcg/kg as a single IV bolus 3 times a week after each', 'dialysis session for up to 52 weeks.', 'STUDY DURATION', 'Double-blind Phase:', 'Screening Period: up to 4 weeks (Screening Visit may occur during', 'Run-in Period at the discretion of Investigator) inclusive of the 7-day', 'Run-in Period', 'Double-blind Treatment Period: 12 weeks', 'Open-label Extension Phase: up to 52 weeks', 'Follow-up Period: 7-10 days', 'Total study duration for a single patient: up to approximately 70 weeks', 'STUDY', 'Efficacy Endpoints', 'ENDPOINTS', 'Primary Efficacy Endpoint', 'Proportion of patients achieving at least a 3-point improvement', 'from baseline with respect to the weekly mean of the daily 24-', 'hour Worst Itching Intensity NRS score at Week 12 of the', 'Double-blind Treatment Period', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 11 of 92', 'CR845-CLIN3103', 'Secondary Efficacy Endpoints', 'Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 12 of the Double-blind', 'Treatment Period.', 'Proportion of patients achieving >3-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 8 of the Double-blind', 'Treatment Period.', 'Proportion of patients achieving 3-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 4 of the Double-blind', 'Treatment Period.', 'Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 8 of the Double-blind', 'Treatment Period.', 'Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 4 of the Double-blind', 'Treatment Period.', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the Skindex-10 Scale total score', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the 5-D Itch Scale total score', 'Additional efficacy endpoints are described in Section 8.7.4.', 'Safety Endpoints', 'The safety endpoints used to evaluate the overall safety and tolerability', 'of CR845 will be adverse events, ECG, vital signs, and clinical safety', 'laboratory evaluations.', 'INTERIM', 'Safety data will be reviewed on an ongoing basis by the Sponsor and a', 'ASSESSMENT', 'Data Safety Monitoring Board (DSMB). The operation of the DSMB', '(Double-blind Phase)', \"will be governed by a charter that will describe the group's meeting\", 'frequency, procedures, and requirements for reporting its observations', 'to the Sponsor. The DSMB will not be part of the study team and will', 'receive unblinded safety results on a regular basis.', 'A single interim assessment for sample size re-estimation is planned', 'after approximately 50% of the first 350 randomized patients either', 'complete the 12-week Double-blind Treatment Period or discontinue', 'study drug prematurely. The interim assessment will be conducted by', 'an Independent Data Monitoring Committee (IDMC). Members of the', 'IDMC will not participate in the DSMB and will not be members of the', 'study team. During the interim assessment, the study team will remain', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}